BunyaVax
BunyaVax exploits proprietary technology to develop safe and efficacious vaccines against neglected diseases of animals and humans, focusing on viral pathogens affecting animal and human health in developing countries. The company collaborates with CEPI and leading pharma to create vaccines that combine efficacy with safety, especially targeting bunyaviruses and other insect- and tick-borne viruses.
Industries
Nr. of Employees
small (1-50)
BunyaVax
Products
Rift Valley fever vaccine candidate (four-segmented live-attenuated)
A live-attenuated Rift Valley fever vaccine candidate generated by splitting the M genome segment to create a four-segmented virus and removing major virulence factors; shown to induce sterile immunity and exhibit an improved safety profile in multiple animal species.
Influenza vaccine candidate (RNA-particle based)
Preclinical influenza vaccine using RNA particles expressing influenza hemagglutinin that are replication-competent but non-spreading; demonstrated single-dose protection in mice via intramuscular or intranasal administration.
RNA-particle cancer immunotherapy candidates
Preclinical RNA-particle constructs encoding tumor-associated epitopes that activate human dendritic cells and CD8+ T cells and can control tumor outgrowth in mouse models.
Rift Valley fever vaccine candidate (four-segmented live-attenuated)
A live-attenuated Rift Valley fever vaccine candidate generated by splitting the M genome segment to create a four-segmented virus and removing major virulence factors; shown to induce sterile immunity and exhibit an improved safety profile in multiple animal species.
Influenza vaccine candidate (RNA-particle based)
Preclinical influenza vaccine using RNA particles expressing influenza hemagglutinin that are replication-competent but non-spreading; demonstrated single-dose protection in mice via intramuscular or intranasal administration.
RNA-particle cancer immunotherapy candidates
Preclinical RNA-particle constructs encoding tumor-associated epitopes that activate human dendritic cells and CD8+ T cells and can control tumor outgrowth in mouse models.
Services
Collaborative development of vaccine candidates using live-attenuated and RNA-particle platforms with adaptable antigen expression for human and veterinary applications.
Development of high-sensitivity, high-specificity virus neutralization assays using attenuated reporter-expressing viral constructs.
Licensing of commercial rights and transfer of veterinary vaccine programs to animal health companies.
Collaborative development of vaccine candidates using live-attenuated and RNA-particle platforms with adaptable antigen expression for human and veterinary applications.
Development of high-sensitivity, high-specificity virus neutralization assays using attenuated reporter-expressing viral constructs.
Licensing of commercial rights and transfer of veterinary vaccine programs to animal health companies.
Expertise Areas
- Live-attenuated vaccine development
- RNA-particle vaccine platforms
- Preclinical and early-phase clinical evaluation
- Viral reverse genetics and genome engineering
Key Technologies
- Four-segment genome engineering (genome segmentation)
- Reverse genetics
- Replication-competent non-spreading RNA particles
- GFP-reporter virus neutralization tests
News & Updates
CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against Rift Valley Fever.
The first healthy volunteer was dosed in a Phase I human trial of the Rift Valley fever vaccine developed by BunyaVax.
Jeroen Kortekaas resigned as CSO of BunyaVax as of 31 Aug 2021, after serving since September 2017.
CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against Rift Valley Fever.
The first healthy volunteer was dosed in a Phase I human trial of the Rift Valley fever vaccine developed by BunyaVax.
Jeroen Kortekaas resigned as CSO of BunyaVax as of 31 Aug 2021, after serving since September 2017.